GERN
HEALTHCAREGeron Corp
$1.58-0.07 (-4.24%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving GERN Today?
No stock-specific AI insight has been generated for GERN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.04$2.01
$1.58
Fundamentals
Market Cap$1.0B
P/E Ratio—
EPS$-0.13
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin-0.5%
Debt / Equity—
Trading
Volume21.5M
Avg Volume (10D)—
Shares Outstanding640.9M
GERN News
20 articles- A Look At Geron (GERN) Valuation After Q1 Results And Reaffirmed 2026 GuidanceYahoo Finance·May 8, 2026
- Geron Corporation (NASDAQ:GERN) Just Reported And Analysts Have Been Lifting Their Price TargetsYahoo Finance·May 8, 2026
- Geron Corporation Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Geron Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Geron (GERN) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business HighlightsYahoo Finance·May 6, 2026
- Geron Plans to Present at Upcoming Investor ConferencesYahoo Finance·May 5, 2026
- Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal OfficerYahoo Finance·Apr 25, 2026
- Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026Yahoo Finance·Apr 22, 2026
- Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 20, 2026
- Geron Adds Chief Legal Officer As Equity Ties To Execution RiskYahoo Finance·Apr 15, 2026
- Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 14, 2026
- Geron Highlights RYTELO Launch, 2026 Revenue Outlook and Phase 3 Myelofibrosis Plans at Needham ConfMarketbeat·Apr 14, 2026
- Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate SecretaryGlobeNewswire Inc.·Apr 13, 2026
- Geron to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire Inc.·Apr 6, 2026
- Geron Adds Biopharma Veterans As RYTELO Focus And Valuation Draw AttentionYahoo Finance·Mar 29, 2026
- Geron Announces Appointment of New Members to its Board of DirectorsYahoo Finance·Mar 26, 2026
- Geron Details RYTELO Growth Plan, $220M-$240M 2026 Sales Guide and MF Trial Catalyst at Barclays ConferenceMarketbeat·Mar 17, 2026
- Geron Corporation (GERN) Reports Q4 EPS of (5c)Yahoo Finance·Mar 12, 2026
- How The Geron (GERN) Story Is Shifting After Target Cut And New Equity PlansYahoo Finance·Mar 10, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$1.65
Day High$0.00
Day Low$0.00
52 Week High$2.01
52 Week Low$1.04
52-Week Range
$1.04$2.01
$1.58
Fundamentals
Market Cap$1.0B
P/E Ratio—
EPS$-0.13
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin-0.5%
Debt / Equity—
Trading
Volume21.5M
Avg Volume (10D)—
Shares Outstanding640.9M
About Geron Corp
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—